Takeda Pharmaceutical Co. and H. Lundbeck A/S are teaming up to ensure a bright outlook for their major depressive disorder treatment Trintellix.
Japan-based Takeda and Denmark-based Lundbeck, which comarket Trintellix (vortioxetine hydrobromide), filed five separate patent infringement lawsuits against generic drugmakers including Cadila Healthcare Ltd. and its subsidiary Zydus Pharmaceuticals USA Inc., Cipla Ltd., Prinston Pharmaceutical Inc. and Torrent Pharmaceuticals Ltd. The lawsuit seeks to block the Food and Drug Administration’s approval of generic copies of the top-selling drug.
The companies are seeking to protect their valuable Trintellix franchise from generic competition until the last of the patents expires in ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.